GO
Loading...

Latest Video

Merck & Pfizer beat the Street     Tue, 29 Jul '14 | 10:14 AM ET

CNBC's Meg Tirrell reports both Merck and Pfizer beat earnings expectations amid patent expirations.

Uber targets corporate travel     Tue, 29 Jul '14 | 10:13 AM ET

CNBC's Josh Lipton reports Uber is debuting "Uber for Business" which aims to make it easier for users to bill trips to their company while working.

Focus on GDP: Strategist     Tue, 29 Jul '14 | 10:04 AM ET

Discussing today's better-than-expected consumer confidence data, Fed rate expectations and this week's GDP report, with David Zervos, Jefferies chief market strategist.

Marc Faber, editor of the "Gloom, Boom & Doom Report," has been calling for a major stock market correction, even a 1987-style crash, for several years. Here are his most bearish calls.

CNBC's Steve Liesman reveals the latest findings from a CNBC survey on the prediction for stocks and bonds, and when the Fed will hike rates.

July consumer confidence index 90.9     Tue, 29 Jul '14 | 10:00 AM ET

CNBC's Rick Santelli reports the latest consumer confidence data.

Cramer's Stop Trading: IDTI pops     Tue, 29 Jul '14 | 9:55 AM ET

CNBC's Jim Cramer explains why he is watching Integrated Device Technology.

Why are rates moving so low?     Tue, 29 Jul '14 | 9:46 AM ET

CNBC's Rick Santelli discusses the latest action in the bond market, and the U.S. dollar, on the first day of the 2-day Federal Reserve meeting.

CNBC's Bob Pisani reports on record low rates in Europe, and Masco's earnings beat.

CNBC's Meg Tirrell spoke with Merck CEO Ken Frazier after earnings. Frazier spoke about the competition in hepatitis C, industry consolidation and shared his opinions on the U.S. tax system.

BP is warning if Russian sanctions get more serious, they could feel an impact, with the "Squawk on the Street" crew.

Windstream spinning off assets     Tue, 29 Jul '14 | 9:30 AM ET

CNBC's David Faber provides insight to news Windstream is spinning off its assets into a publicly traded REIT. Jim Cramer looks at other stocks reacting to the announcement.

Jim Cramer explains what to watch ahead of the open, including Darden Restaurants.

Robert Shiller: New anxieties at work     Tue, 29 Jul '14 | 9:14 AM ET

Robert Shiller, Case-Shiller Index co-founder and Yale University professor of economics, discusses today's key housing data that showed U.S. home price gains are weakening. Shiller also weighs in on the economic headwinds developing from real estate.

Cramer: Stay long Merck     Tue, 29 Jul '14 | 9:06 AM ET

The "Squawk on the Street" news team discusses the quarterly results of Merck and Pfizer.

Windstream to spin assets into REIT     Tue, 29 Jul '14 | 9:00 AM ET

CNBC's David Faber and Jim Cramer discuss Windstream's spin-off of assets into a publicly traded REIT.

Martin Mucci, Paychex CEO, discusses the latest employment trends and provides a read on job growth.

Cramer: Windstream interesting     Tue, 29 Jul '14 | 8:49 AM ET

CNBC's Jim Cramer shares his thoughts on earnings and where he sees investment opportunities.

Aecom buys Hunt Construction Group     Tue, 29 Jul '14 | 8:42 AM ET

Michael Burke, Aecom Technology CEO, discusses the acquisition of Hunt Construction and the business of infrastructure.

Split decision on Fed policy: Survey     Tue, 29 Jul '14 | 8:32 AM ET

CNBC's Steve Liesman reveals finding from CNBC's exclusive survey on the outcome of Federal Reserve policy.

Twitter, down but not out     Tue, 29 Jul '14 | 8:22 AM ET

Youssef Squali, Cantor Fitzgerald, shares his outlook on Twitter and explains why he think the social media company can still make a comeback.

Where to take interest rate risk     Tue, 29 Jul '14 | 8:16 AM ET

Jeffrey Rosenberg, BlackRock's chief investment strategist, shares his thoughts on how to increase returns amid a low-rate environment.

Big pharma tax attack     Tue, 29 Jul '14 | 8:04 AM ET

Fundamentally, U.S.-based companies are at a disadvantage because of our tax code, says Barbara Ryan, FTI Consulting, sharing her thoughts on tax inversion among the big pharma space.

Big pharma by the numbers     Tue, 29 Jul '14 | 8:02 AM ET

What we are seeing is innovation is not dead, says Barbara Ryan, FTI Consulting, discussing Pfizer and Merck's second quarter results and big Pharma drug trends.

Hilton Hotels goes high-tech     Tue, 29 Jul '14 | 7:44 AM ET

Christopher Nassetta, Hilton Worldwide president & CEO, says Hilton Hotels are revolutionizing the hotel experience by offering guests the ability to check-in, select rooms and customize the hospitality experience all from their smartphones.

Living in a bank settlement world     Tue, 29 Jul '14 | 7:31 AM ET

There's been a tremendous increase in the states getting involved in areas of regulations they did not usually get involved in before, says Eric Dinallo, Debevosie & Plimpton LLP partner, discussing banking regulations.

UBS CFO on litigation     Tue, 29 Jul '14 | 7:21 AM ET
Tom Naratil, CFO of UBS AG

Tom Naratil, UBS CFO, discusses UBS's settlement with Germany on tax evasion charges.

UBS CFO on wealth management     Tue, 29 Jul '14 | 7:18 AM ET

Tom Naratil, UBS CFO, discusses robust growth in UBS's wealth management division.

Jeffrey Rosenberg, BlackRock, shares his thoughts on Fed policy ahead of the FOMC meeting. We no longer need negative two percent interest rates and a massive size balance sheet, says Rosenberg.

Ahead of the Fed: Survey     Tue, 29 Jul '14 | 7:02 AM ET

CNBC's Steve Liesman provides the results of CNBC's survey on what to expect from the Fed before this week's FOMC meeting.

Contact Latest Video

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    › Learn More

Video and TV

  • Jeffrey Rosenberg, BlackRock's chief investment strategist, shares his thoughts on how to increase returns amid a low-rate environment.

  • The Apple logo is displayed at the Upper West Side Apple store in New York.

    CNBC's Josh Lipton and USA Today San Francisco Bureau Chief Jon Swartz discuss what Apple's acquisition plans say about its hardware business.

  • What we are seeing is innovation is not dead, says Barbara Ryan, FTI Consulting, discussing Pfizer and Merck's second quarter results and big Pharma drug trends.

U.S. Video

Asia Video

Europe Video